{
    "nct_id": "NCT01757717",
    "official_title": "A Pilot Study of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Patients must have histologic proof of a malignancy suitable for radiation therapy.\n* Patients must have received prior external beam radiation therapy to the region proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration.\n* If repeat irradiation would exceed any normal tissue constraint set by MSKCC Radiation Oncology Department dose constraint criteria, the patient will potentially be eligible.\n* If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/α/β), where n = number of fractions and d = dose per fraction; α/β is the constant for spinal cord late effect and equals 2. \\[Rades 2005, Nieder 2005, Sahgal 2012\\]\n* KPS ≥ 60\n* Age ≥ 18 years old\n\nExclusion Criteria:\n\n* Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria.\n* Patients with kyphoplasty cement or hardware that would preclude effective catheter placement.\n* Patients with paraspinal extension of disease with visceral involvement.\n* Abnormal complete blood count. Any of the following:\n* Platelet count \\< 75,000/ml\n* Hb level \\< 9gm/dl\n* WBC \\< 3.5/ml\n* Abnormal coagulation profile: INR \\> 2.5 and/or PTT \\> 80\n* Patients who are on anticoagulation medication that may not be safely held for the procedure (≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin formulations) will be excluded.\n* Contraindications to general anesthesia\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Patients must have histologic proof of a malignancy suitable for radiation therapy.\n* Patients must have received prior external beam radiation therapy to the region proposed for HDR brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration.\n* If repeat irradiation would exceed any normal tissue constraint set by MSKCC Radiation Oncology Department dose constraint criteria, the patient will potentially be eligible.\n* If the total prior radiation dose to the cord or pelvis exceeds 100 Gy BED equivalent, the patient will be potentially eligible, where a total of 100 BED Gy equivalent is determined by the biological equivalent dose (BED) calculation; BED = nd(1 + d/α/β), where n = number of fractions and d = dose per fraction; α/β is the constant for spinal cord late effect and equals 2. [Rades 2005, Nieder 2005, Sahgal 2012]\n* KPS ≥ 60\n* Age ≥ 18 years old",
        "exclusion": "* Patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by MSKCC Radiation Oncology Department dose constraint criteria.\n* Patients with kyphoplasty cement or hardware that would preclude effective catheter placement.\n* Patients with paraspinal extension of disease with visceral involvement.\n* Abnormal complete blood count. Any of the following:\n* Platelet count < 75,000/ml\n* Hb level < 9gm/dl\n* WBC < 3.5/ml\n* Abnormal coagulation profile: INR > 2.5 and/or PTT > 80\n* Patients who are on anticoagulation medication that may not be safely held for the procedure (≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin formulations) will be excluded.\n* Contraindications to general anesthesia"
    }
}